Annovis Cash per Share

ANVS -  USA Stock  

USD 8.61  0.53  5.80%

Annovis Bio fundamentals help investors to digest information that contributes to Annovis Bio's financial success or failures. It also enables traders to predict the movement of Annovis Stock. This fundamental analysis module provides a way for investors to measures Annovis Bio's intrinsic value by examining all of its available economic and financial indicators and drivers, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Annovis Bio stock. Please note, this module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.
  
Refresh
As of 05/27/2022, Free Cash Flow is likely to drop to about (9.4 M).

Annovis Cash per Share Analysis

Annovis Bio's Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.
Cash per Share 
 = 
Total Cash 
Average Shares 
More About Cash per Share | All Equity Analysis

Current Annovis Bio Cash per Share

    
  5.60 X  
Most of Annovis Bio's fundamental indicators, such as Cash per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Annovis Bio is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Annovis Cash per Share Driver Correlations

Understanding the fundamental principles of building solid financial models for Annovis Bio is extremely important. It helps to project a fair market value of Ford stock properly, considering its historical fundamentals such as Cash per Share. Since Annovis Bio's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Annovis Bio's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Annovis Bio's interrelated accounts and indicators.
Companies with high Cash per Share ratio will be considered as an attractive investment by most investors. In most industries if you can single out an equity instrument trading below its cash per share value, you have a bargain and should consider buying it. Finding the stocks traded below their cash value, therefore, can be a good starting point for investors using strategies based on fundamentals.
Compare to competition

Annovis Shareholders Equity

Shareholders Equity

48.01 Million

Share
Annovis Bio Shareholders Equity is relatively stable at the moment as compared to the past year. Annovis Bio reported last year Shareholders Equity of 44.49 Million
In accordance with the recently published financial statements, Annovis Bio has a Cash per Share of 5.6 times. This is 28.74% higher than that of the Healthcare sector and 29.33% higher than that of the Biotechnology industry. The cash per share for all United States stocks is 11.78% lower than that of the firm.

Annovis Cash per Share Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Annovis Bio's direct or indirect competition against its Cash per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Annovis Bio could also be used in its relative valuation, which is a method of valuing Annovis Bio by comparing valuation metrics of similar companies.
Annovis Bio is currently under evaluation in cash per share category among related companies.

Annovis Fundamentals

About Annovis Bio Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Annovis Bio's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Annovis Bio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Annovis Bio based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Last ReportedProjected for 2022
Free Cash Flow-9.1 M-9.4 M
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania. Annovis Bio operates under Biotechnology classification in the United States and is traded on New York Stock Exchange. It employs 3 people.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Annovis Bio without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Portfolio Volatility Now

   

Portfolio Volatility

Check portfolio volatility and analyze historical return density to properly model market risk
All  Next Launch Module

Pair Trading with Annovis Bio

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Annovis Bio position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Annovis Bio will appreciate offsetting losses from the drop in the long position's value.

Annovis Bio Pair Correlation

Correlation Analysis For Direct Indexing and Tax-loss Harvesting

The ability to find closely correlated positions to Annovis Bio could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Annovis Bio when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Annovis Bio - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Annovis Bio to buy it.
The correlation of Annovis Bio is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Annovis Bio moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Annovis Bio moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Annovis Bio can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Please continue to Annovis Bio Piotroski F Score and Annovis Bio Altman Z Score analysis. Note that the Annovis Bio information on this page should be used as a complementary analysis to other Annovis Bio's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.

Complementary Tools for Annovis Stock analysis

When running Annovis Bio price analysis, check to measure Annovis Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Annovis Bio is operating at the current time. Most of Annovis Bio's value examination focuses on studying past and present price action to predict the probability of Annovis Bio's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Annovis Bio's price. Additionally, you may evaluate how the addition of Annovis Bio to your portfolios can decrease your overall portfolio volatility.
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Go
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Go
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Go
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Go
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Go
ETF Directory
Find actively traded Exchange Traded Funds (ETF) from around the world
Go
Is Annovis Bio's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Annovis Bio. If investors know Annovis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Annovis Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Annovis Bio is measured differently than its book value, which is the value of Annovis that is recorded on the company's balance sheet. Investors also form their own opinion of Annovis Bio's value that differs from its market value or its book value, called intrinsic value, which is Annovis Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Annovis Bio's market value can be influenced by many factors that don't directly affect Annovis Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Annovis Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine Annovis Bio value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Annovis Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.